Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

BACKGROUND: Multiple myeloma remains an incurable disease with multiple relapses due to residual myeloma cells in the bone marrow of patients after therapy. Presence of small number of cancer cells in the body after cancer treatment, called minimal residual disease, has been shown to be prognostic f...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmitz, Alexander, Brøndum, Rasmus Froberg, Johnsen, Hans Erik, Mellqvist, Ulf-Henrik, Waage, Anders, Gimsing, Peter, op Bruinink, Davine Hofste, van der Velden, Vincent, van der Holt, Bronno, Hansson, Markus, Andersen, Niels Frost, Frølund, Ulf Christian, Helleberg, Carsten, Schjesvold, Fredrik H., Ahlberg, Lucia, Gulbrandsen, Nina, Andreasson, Bjorn, Lauri, Birgitta, Haukas, Einar, Bødker, Julie Støve, Roug, Anne Stidsholt, Bøgsted, Martin, Severinsen, Marianne T., Gregersen, Henrik, Abildgaard, Niels, Sonneveld, Pieter, Dybkær, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818194/
https://www.ncbi.nlm.nih.gov/pubmed/35123422
http://dx.doi.org/10.1186/s12885-022-09184-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818194/
https://www.ncbi.nlm.nih.gov/pubmed/35123422
http://dx.doi.org/10.1186/s12885-022-09184-1

Ejemplares similares